tiprankstipranks
In this article:
Blurbs

Wall Street Analysts Are Bullish on Top Healthcare Picks

In this article:
In this article:

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Co-Diagnostics (CODXResearch Report), Tempest Therapeutics (TPSTResearch Report) and Biogen (BIIBResearch Report) with bullish sentiments.

Co-Diagnostics (CODX)

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Co-Diagnostics, with a price target of $15.00. The company’s shares closed last Thursday at $6.83, close to its 52-week low of $6.48.

According to TipRanks.com, Chen is a 5-star analyst with an average return of 16.8% and a 35.3% success rate. Chen covers the Healthcare sector, focusing on stocks such as Ortho Clinical Diagnostics Holdings, Interpace Diagnostics Group, and HTG Molecular Diagnostics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Co-Diagnostics with a $14.50 average price target.

See today’s best-performing stocks on TipRanks >>

Tempest Therapeutics (TPST)

In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Tempest Therapeutics, with a price target of $51.00. The company’s shares closed last Thursday at $3.64, close to its 52-week low of $3.16.

According to TipRanks.com, Pantginis ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -18.8% and a 23.8% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Tempest Therapeutics with a $51.00 average price target.

Biogen (BIIB)

H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Biogen today and set a price target of $270.00. The company’s shares closed last Thursday at $220.17, close to its 52-week low of $212.56.

According to TipRanks.com, Fein ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -3.7% and a 34.0% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Amylyx Pharmaceuticals, Inc., and Deciphera Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Biogen with a $282.95 average price target, implying a 31.6% upside from current levels. In a report issued on January 27, Jefferies also assigned a Buy rating to the stock with a $300.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CODX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed